Condition: Chronic Kidney Disease(CKD) · Uncontrolled Hypertension · Sponsor: University Hospital, Tours
Chronic kidney disease (CKD) is a major public health issue worldwide. Hypertension is the first risk factor in patients with CKD for mortality, cardiovascular disease and end-stage renal disease. It's now well established that lowering blood pressure (BP) reduces renal and cardiovascular complications in this high-risk population. In the general population, in addition to lifestyle interventions, the strategy to initiate and escalate a BP-lowering drug treatment is well described. The drug therapies recommended to achieve optimal BP control in the general population are the following: blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)), diuretics (thiazides and thiazide-like diuretics), and calcium channel blockers. For patients with CKD, the guidelines advise to start the BP-lowering agent with ACEi or ARB, but then, there is no strong evidence to support the preferential use of any particular agent in controlling BP and the results of clinical trials are discordant. In the NephroTest cohort, a French cohort of patients with CKD stage 1 to 5, among 2015 patients, 1782 had hypertension, only 54% had a diuretic and 44% had uncontrolled hypertension. In this cohort, extracellular fluid (ECF) overload was an independent determinant of hypertension, uncontrolled hypertension and apparent treatment resistant hypertension. In the same cohort, ECF overload was independently associated with end-stage kidne…
This description comes directly from the study's public registry record.
Bénédicte Sautenet, MD · 02.34.37.96.86 · benedicte.sautenet@gmail.com
Always discuss trial participation with your own doctor first.
| Department of Nephrology, University Hospital of Angers | Angers, France | Recruiting |
| Department of Nephrology, University Hospital of Bordeaux | Bordeaux, France | Recruiting |
| AUB Santé foundation, Brest | Brest, France | Recruiting |
| Department of Nephrology, University Hospital of Brest | Brest, France | Recruiting |
| Department of Nephrology, Hospital of Chalon-sur-Saône | Chalon-sur-Saône, France | Recruiting |
| Department of Nephrology, Hospital of Chartres | Chartres, France | Recruiting |
| Department of Nephrology, University Hospital of Clermont-Ferrand | Clermont-Ferrand, France | Recruiting |
| Department of Nephrology, Hospital of Colmar | Colmar, France | Recruiting |
| Department of Nephrology, University Hospital of Grenoble | Grenoble, France | Recruiting |
| Department of Nephrology, Hospital of Haguenau | Haguenau, France | Recruiting |
| Department of Nephrology, Departemental Hospital of Vendée | La Roche-sur-Yon, France | Recruiting |
| ECHO Santé Association, Le Mans | Le Mans, France | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05732727